AbbVie Inc. (ABBV) |
166.41 1.75 (1.06%) 04-19 16:00 |
Open: | 165.02 |
High: | 166.6 |
Low: | 163.25 |
Volume: | 5,526,776 |
Market Cap: | 294,654(M) |
PE Ratio: | 61.18 |
Exchange: | New York Stock Exchange |
Industry: | Drug Manufacturers - General |
Sector: | Healthcare |
Technical analysis | ||||
sell | buy |
Resistance 2: | 182.30 |
Resistance 1: | 173.78 |
Pivot price: | 170.04 |
Support 1: | 160.00 |
Support 2: | 133.12 |
52w High: | 182.89 |
52w Low: | 130.96 |
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
EPS | 2.730 |
Book Value | 5.870 |
PEG Ratio | 2.35 |
Gross Profit | 0.000 |
Profit Margin (%) | 8.95 |
Operating Margin (%) | 31.81 |
Return on Assets (ttm) | 8.1 |
Return on Equity (ttm) | 35.2 |
Thu, 18 Apr 2024
AbbVie buyout Cerevel marks trial win for Parkinson's drug - Seeking Alpha
Wed, 17 Apr 2024
AbbVie (ABBV) Increases Despite Market Slip: Here's What You Need to Know - Yahoo Finance
Wed, 17 Apr 2024
Medincell and AbbVie enter injectable therapy development deal - Pharmaceutical Technology
Tue, 16 Apr 2024
AbbVie Inc. stock outperforms competitors on strong trading day - MarketWatch
Tue, 16 Apr 2024
AbbVie: Through Humira's Crisis Towards Solid Growth (NYSE:ABBV) - Seeking Alpha
Tue, 16 Apr 2024
Fake Botox Fight Sends AbbVie (NASDAQ:ABBV) Up Fractionally - TipRanks.com - TipRanks
StockChart iOS |
StoxlineLite iOS |
StoxlineLite iOS |
OptionCalc iOS |
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |